Johnson & Johnson (JNJ) News
Follow Johnson & Johnson (JNJ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 184 public stories across 58 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Wall Street Rises as Anthropic IPO Report Puts AI in Focus
US stocks are rising, with AI in focus after a report about an Anthropic IPO.
EQUITY | Oct 26, 2026, 02:59 PM UTC
M
China Approves Bayer Drug to Prevent Stroke
Bayer shares rose sharply after China approved its drug for stroke prevention.
REGULATION | Oct 26, 2026, 01:34 PM UTC
L
J&J Says Experimental Prostate Cancer Drug Shrunk Tumors in Early-Stage Trial
Johnson & Johnson said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J gained access to the drug through its $3.05 billion deal to buy Halda Therape
EQUITY | Oct 26, 2026, 10:25 AM UTC
M
Johnson & Johnson Reports 75% Tumor Response Rate for JNJ-6143
Johnson & Johnson reported a 75% tumor response rate for its investigational JNJ-6143 in advanced prostate cancer.
EQUITY | Oct 26, 2026, 08:54 AM UTC
M
Johnson & Johnson Reports 77% Tumor Response Rate in Cancer Trial
Johnson & Johnson reported a 77% tumor response rate in a head and neck cancer trial.
EQUITY | Oct 26, 2026, 08:39 AM UTC
M
Nanobiotix Reports 41.7% Response Rate for JNJ-1900 Melanoma Study
Nanobiotix reported a 41.7% response rate for JNJ-1900 in a Phase I study of anti-PD-1-resistant melanoma.
EQUITY | Oct 26, 2026, 08:38 AM UTC
L
UK Approves Johnson & Johnson’s Oral Psoriasis Pill
Britain’s medicines regulator approved Johnson & Johnson’s daily pill for adults and teenagers with moderate-to-severe plaque psoriasis.
REGULATION | Oct 23, 2026, 12:09 PM UTC
M
Smith & Nephew-J&J Orthopaedics Merger Talks Collapse, FT Reports
The Financial Times reported that talks to combine Smith & Nephew with Johnson & Johnson’s orthopaedics division fell apart after Smith & Nephew rejected a proposal for its former CEO to lead the merged business.
MNA | Oct 23, 2026, 07:19 AM UTC
M
Smith & Nephew-J&J Orthopaedics Merger Talks Collapse
The proposed combination, which would have created a $34 billion transatlantic medical technology company, unravelled after Smith & Nephew refused to agree to its former CEO leading the merged business, the Financial Tim
MNA | Oct 23, 2026, 06:37 AM UTC
M
Wall Street Rises as Healthcare Stocks Rally and Oil Retreats
U.S. main indexes moved higher Tuesday, supported by a surge in healthcare stocks and softer oil prices, extending a recovery from last week's technology-led selloff. Brent crude slipped 1.1% after touching a five-month
EQUITY | Oct 20, 2026, 04:38 PM UTC
L
Johnson & Johnson reports TREMFYA fistula remission data
New data show TREMFYA delivered durable fistula remission through 48 weeks in Crohn’s disease patients with perianal fistula; the announcement describes it as the only IL-23 to do so.
EQUITY | Oct 19, 2026, 12:00 PM UTC
M
Johnson & Johnson Q3 Results Prompt Mixed Analyst Reactions
Johnson & Johnson reported third-quarter sales of $25.4 billion and non-GAAP EPS of $2.59. The company raised its 2026 sales and non-GAAP EPS guidance, though analysts said parts of the outlook and product mix were disap
EQUITY | Oct 14, 2026, 05:45 PM UTC
M
Johnson & Johnson Raises Full-Year Guidance After Q3 Results
Johnson & Johnson reported Q3 adjusted earnings of $2.59 per share and sales of $25.39 billion, then raised its full-year adjusted earnings outlook to $11.05-$11.15 per share and sales outlook to $101 billion-$101.40 bil
EQUITY | Oct 14, 2026, 05:06 PM UTC
M
Johnson & Johnson Raises Outlook as MedTech Sales Miss, Shares Slide
Johnson & Johnson reported better-than-expected profit and raised its full-year outlook, while MedTech sales of $8.64 billion came in below the $8.71 billion analyst estimate. Shares fell 5.73% to $248.61.
EARNINGS | Oct 14, 2026, 01:21 AM UTC
M
Johnson & Johnson Shares Fall 4.7% Despite Higher 2026 Guidance
Johnson & Johnson raised its 2026 adjusted earnings guidance midpoint to $11.10, while shares fell approximately 4.7% to $251.36 on October 13.
EQUITY | Oct 13, 2026, 09:26 PM UTC
M
Wall Street Edges Lower as Chip Stocks Fall
US stocks edged lower as chip shares came under selling pressure, while investors assessed quarterly results from major banks.
EQUITY | Oct 13, 2026, 05:19 PM UTC
M
Johnson & Johnson Raises 2026 Outlook, Sees Drug Deals Cutting 2027 EPS
Johnson & Johnson raised its 2026 sales outlook to $101 billion-$101.40 billion and adjusted earnings guidance to $11.05-$11.15 per share. It expects the Firefly Bio acquisition and Sail Biomedicines collaboration to red
EARNINGS | Oct 13, 2026, 03:11 PM UTC
M
Johnson & Johnson Shares Fall More Than 5% After MedTech Results Miss
Johnson & Johnson shares fell more than 5% Tuesday morning after the company reported weaker-than-expected results from its medical devices division. CFO Joe Wolk said on the earnings call that MedTech performance needs
EARNINGS | Oct 13, 2026, 03:06 PM UTC
M
Johnson & Johnson Raises 2026 Sales Growth Guidance After Q3 Results
Johnson & Johnson reported third-quarter operational sales growth of 6% and revenue above $25 billion. The company raised its full-year 2026 operational sales growth outlook to 6.7%–7.1%.
EQUITY | Oct 13, 2026, 02:02 PM UTC
M
Johnson & Johnson Reports Quarterly Results for Quarter Ended September 30
A machine-generated LSEG summary of Johnson & Johnson’s quarterly results was published. The supplied text provides no results figures.
EQUITY | Oct 13, 2026, 01:32 PM UTC
M
S&P 500 Futures Point to Muted Open as Chip Weakness Weighs
The S&P 500 was set for a muted open as investors assessed big-bank earnings and weakness in chip stocks weighed on Nasdaq futures.
EQUITY | Oct 13, 2026, 01:11 PM UTC
M
Johnson & Johnson Reports Q3 Sales of $25.4B, Raises 2026 Guidance
Third-quarter 2026 sales rose 5.9% year over year to $25.4 billion. Adjusted diluted EPS was $2.59; reported diluted EPS was $0.09, reflecting one-time special items. The company raised full-year 2026 guidance.
EQUITY | Oct 13, 2026, 12:13 PM UTC
M
Johnson & Johnson Reports Third-Quarter EPS of 9 Cents
Johnson & Johnson reported third-quarter EPS of 9 cents, down from $2.12 a year earlier. Results included a one-time charge for a proposed talc litigation resolution, along with charges tied to its Firefly Bio acquisitio
EARNINGS | Oct 13, 2026, 11:07 AM UTC
M
Johnson & Johnson Reports Tremfya Sales Growth of 68.2% in 3Q
Tremfya worldwide operational sales reached $2.4 billion, up 68.2% in the third quarter, helping cushion Stelara sales erosion.
EARNINGS | Oct 13, 2026, 11:07 AM UTC
M
Johnson & Johnson Raises Full-Year Earnings Guidance After Q3 Beat
Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share, above expectations, and raised its full-year outlook. Medical technology business stumbles left investors lukewarm.
EQUITY | Oct 13, 2026, 11:07 AM UTC
M
Johnson & Johnson Reports Higher-Than-Expected Profit as Device Sales Face Pressure
Johnson & Johnson reported a slightly higher-than-expected profit, driven by strong sales of Tremfya. The Middle East conflict weighed on its medical devices business.
EARNINGS | Oct 13, 2026, 10:58 AM UTC
M
Johnson & Johnson 3Q MedTech Sales Reach $8.64B
Johnson & Johnson reported worldwide MedTech sales of $8.64 billion for the third quarter.
EARNINGS | Oct 13, 2026, 10:34 AM UTC
M
Johnson & Johnson Declares $1.34 Per-Share Fourth-Quarter Dividend
The dividend is payable December 8, 2026, to shareholders of record at the close of business on November 24.
EQUITY | Oct 13, 2026, 10:25 AM UTC
M
Johnson & Johnson Raises 2026 Adjusted EPS View
Johnson & Johnson raised its 2026 adjusted EPS view to $11.05–$11.15, from $10.96–$11.11.
EARNINGS | Oct 13, 2026, 10:22 AM UTC
H
$JNJ Johnson & Johnson Q3 Earnings
Adj. EPS $2.59, est. $2.52 Revenue $24.60B, est. $24.21B MedTech Sales $8.64B, est. $8.77B Medicine Revenue $16.76B, est. $16.59B Darzalex Revenue $4.24B, est. $4.31B FY Adj. EPS Outlook $11.05—$11.15, prior $10.96—$11.1
EARNINGS | Oct 13, 2026, 10:21 AM UTC
M
J&J Reports $16.76B in 3Q Innovative Medicine Sales
Johnson & Johnson reported worldwide Innovative Medicine sales of $16.76 billion in the third quarter.
EARNINGS | Oct 13, 2026, 10:20 AM UTC
M
J&J Reports Higher-Than-Expected Profit as Medical Device Sales Face Middle East Drag
Johnson & Johnson reported a slightly higher-than-expected third-quarter profit, citing strong sales of Tremfya and a drag on its medical devices business from geopolitical issues including the Middle East conflict.
EARNINGS | Oct 13, 2026, 10:20 AM UTC
L
J&J Leans Toward Spinning Out Hips-and-Knees Business
CFO Joseph Wolk said Johnson & Johnson is leaning toward spinning out its hips-and-knees business, which the company has been looking to hive off.
EQUITY | Oct 13, 2026, 10:20 AM UTC
M
Johnson & Johnson Raises 2026 Sales View to $101B–$101.4B
The company previously forecast 2026 sales of $100.8B–$101.4B.
EARNINGS | Oct 13, 2026, 10:20 AM UTC
M
Johnson & Johnson Reports 3Q Orthopaedics Sales of $2.35B
EARNINGS | Oct 13, 2026, 10:20 AM UTC
M
Johnson & Johnson reports 3Q U.S. sales of $14.96B
EARNINGS | Oct 13, 2026, 10:20 AM UTC
M
Johnson & Johnson Reports 3Q Sales of $25.4B
EARNINGS | Oct 13, 2026, 10:20 AM UTC
L
Johnson & Johnson Reports Third-Quarter Net Income of $210 Million
EARNINGS | Oct 13, 2026, 10:20 AM UTC
L
Johnson & Johnson Reports Third-Quarter Adjusted EPS of $2.59
EARNINGS | Oct 13, 2026, 10:20 AM UTC
H
Dow Jones Industrial Average Gets Spotlight: 5 Earnings Reports Representing 25% of ETF’s Assets On Deck
Earnings season kicks off this week as several of the largest financial companies report quarterly financial results. The week is a big one for the Dow Jones Industrial Average, with five of its 30 components reporting.
LIVE | Oct 12, 2026, 04:24 PM UTC
M
Johnson & Johnson Q3'26 Earnings Preview: EPS Estimate 2.52
Johnson & Johnson is scheduled to report Q3'26 results on October 13 before the market opens. Revenue is estimated at 25.38 billion USD and EPS at 2.52 USD.
EQUITY | Oct 12, 2026, 11:00 AM UTC
L
Johnson & Johnson Is Maintained at Neutral by JP Morgan
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 01:40 PM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
H
BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street
BofA Securities raised its price target on Johnson & Johnson NYSE:JNJ to $278 from $263 while keeping a Neutral rating, lifting its forecasts for Icotyde and updating its model for recent in-process research and developm
EARNINGS | Sep 29, 2026, 12:18 PM UTC
L
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
By Blake BrittainA federal judge in Delaware on Monday rejected Pfizer NYSE:PFE, BioNTech NASDAQ:BNTX and Moderna's NASDAQ:MRNA requests to dismiss patent lawsuits filed against them by Bayer's XETR:BAYN Monsanto unit ov
REGULATION | Sep 28, 2026, 06:20 PM UTC
L
Weekly Recap: Intra-Cellular $14.6B deal and JNJ’s Carvykti 50% remissions
Johnson & Johnson (NYSE:JNJ) is integrating its $14.6B Intra-Cellular Therapies buy while weighing Caplyta's expanded label after positive trials, reporting strong Carvykti long-term remission and survival data, completi
NEWS | Sep 28, 2026, 11:07 AM UTC
L
J&J Says Tremfya Meets Primary And Major Secondary Endpoints In Axial PsA Study
Johnson & Johnson NYSE:JNJ
NEWS | Sep 25, 2026, 11:44 AM UTC
L
J&J Gains 1.7% as Caplyta Opens a Mania Expansion Path
Johnson & Johnson NYSE:JNJ, the healthcare and pharmaceutical company, reported positive Phase 3 results for Caplyta in adults with bipolar I mania. Shares rose about 1.5% to $273.18 at 10.55am ET time on Thursday mornin
EQUITY | Sep 24, 2026, 07:31 PM UTC
L
J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro
Johnson & Johnson NYSE:JNJ
NEWS | Sep 23, 2026, 02:34 PM UTC
L
J&J Says In-Development Blood-Cancer Treatment Shows Promise
By Connor HartJohnson & Johnson released data from a late-stage study of its treatment for certain blood cancers, which showed sustained disease control and survival.The drugmaker on Wednesday said its treatment--a combi
NEWS | Sep 23, 2026, 02:20 PM UTC
L
JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/
NEWS | Sep 23, 2026, 01:48 PM UTC
L
AI Biotech Enveda Doubles in Value to $2 Billion — WSJ
By Xavier MartinezEnveda, a privately held AI biotechnology startup, has doubled its valuation to about $2 billion as momentum builds behind tech-driven approaches to discovering new medicines.The financing will help the
NEWS | Sep 23, 2026, 10:00 AM UTC
M
J&J shares rise on Caplyta bipolar mania endpoint result
Johnson & Johnson shares gained about 0.8% to $272.34 Monday after Caplyta hit its primary endpoint in a late-stage bipolar mania study, prompting investors to weigh potential expansion.
EARNINGS | Sep 21, 2026, 07:11 PM UTC
H
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
Johnson & Johnson (NYSE: JNJ ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder. The trial successfully met i
LIVE | Sep 21, 2026, 05:08 PM UTC
M
J&J says Caplyta met main goal in bipolar mania late-stage study
Johnson & Johnson said its experimental Caplyta use for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to potential expansion beyond approved uses. Caplyta was acquired through J&J
EARNINGS | Sep 21, 2026, 12:48 PM UTC
M
Caplyta shows rapid improvement in bipolar mania phase 3 study
EQUITY | Sep 21, 2026, 12:36 PM UTC
H
Novo and Orbis sign up to $1.4B deal for oral therapies
Orbis Medicines signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases traditionally treated with injectable drugs.
MNA | Sep 17, 2026, 11:00 AM UTC
M
Legend Biotech names Ingrid Zhang CEO
Legend Biotech (LEGN) appointed Ingrid Zhang as chief executive on Tuesday, ending a two-month search after former CEO Ying Huang resigned in July.
EQUITY | Sep 15, 2026, 11:40 PM UTC
L
As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ib
REGULATION | Sep 15, 2026, 03:16 PM UTC
H
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ: CTNM ) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical up
LIVE | Sep 15, 2026, 03:07 PM UTC